5/30/2014 | DD | Savient Pharmaceuticals plan of liquidation takes effect as of May 30
|
5/20/2014 | DD | Savient Pharmaceuticals: Plan of liquidation to take effect by May 30
|
5/20/2014 | DD | Savient Pharmaceuticals gets OK of convertibles exchange settlement
|
5/20/2014 | DD | Savient Pharmaceuticals marks $62,592 profit for month ended April 30
|
5/19/2014 | DD | Savient Pharmaceuticals amended plan of liquidation confirmed by court
|
5/13/2014 | DD | Savient Pharmaceuticals seeks stipulation on $2.72 million of claims
|
5/7/2014 | DD | Savient Pharmaceuticals posts $212,165 net loss, zero revenue in April
|
5/5/2014 | DD | Savient Pharmaceuticals plan of liquidation gets objection from IRS
|
4/28/2014 | DD | Savient and Tang agree to drop claims tied to convertibles exchange
|
4/17/2014 | DD | Savient Pharmaceuticals posts $2.7 million net loss for March period
|
3/20/2014 | DD | Savient Pharmaceuticals records $4.21 million net loss for February
|
3/18/2014 | DD | Savient Pharmaceuticals disclosure statement OK'd; plan hearing May 19
|
2/21/2014 | DD | Savient wins exclusivity extension to negotiate and implement plan
|
2/20/2014 | DD | Savient Pharmaceuticals posts $324,071 January profit; revenue falls
|
2/10/2014 | DD | Savient Pharmaceuticals files liquidation plan, disclosure statement
|
2/5/2014 | DD | Savient wins OK of creditor, noteholder collateral dispute settlement
|
2/4/2014 | DD | Savient seeks exclusivity extension to negotiate and implement plan
|
1/21/2014 | DD | Savient Pharmaceuticals records $2.2 million net loss for December
|
1/15/2014 | DD | Savient, unsecured creditors and noteholders settle collateral dispute
|
1/10/2014 | DD | Savient's $120.4 million sale completed; management changes announced
|
1/7/2014 | DD | Savient Pharmaceuticals: Sale assumed to close during week of Jan. 10
|
12/20/2013 | DD | Savient Pharmaceuticals records $2.92 million net loss for November
|
12/13/2013 | DD | Savient Pharmaceuticals wins OK for $120 million asset sale to Crealta
|
12/11/2013 | DD | Savient Pharmaceuticals to sell assets to Crealta for $120.4 million
|
12/10/2013 | DD | Savient Pharmaceuticals inks cash use agreement; settlement proposed
|
12/5/2013 | DD | Savient Pharmaceuticals posts $9.79 million loss for Oct. 15-Oct. 31
|
11/4/2013 | DD | Savient Pharmaceuticals bid procedures OK'd; can also sell Irish units
|
10/25/2013 | DD | Savient Pharmaceuticals' three-member creditors committee appointed
|
10/16/2013 | DD | Savient Pharmaceuticals granted interim access to cash collateral
|
10/15/2013 | CVDDHY | Savient Pharmaceuticals bankrupt, gets $55 million lead bid for assets
|
10/15/2013 | CV | Market Commentary: Midday Commentary: Planned Resource Capital looks cheap; Savient files Chapter 11
|
10/15/2013 | CV | Market Commentary: Savient collapses after bankruptcy filing; MolyCorp drops; Resource, SolarCity on tap
|
3/19/2013 | CVHY | Savient says cash is enough to operate through first half of 2014
|
7/23/2012 | CVDD | Savient says court rules no event of default on 4.75% convertibles
|
6/22/2012 | CV | Market Commentary: Patriot Coal continues to weaken; Onyx extends gains; Royal Gold slips in line; K-V drops
|
6/8/2012 | CVDD | Savient Pharmaceuticals holders allege default on 4.75% convertibles
|
5/9/2012 | CVLM | Savient holders exchange $108 million of 4.75% convertible notes
|
4/4/2012 | CVHYPF | Savient files $100 million shelf covering stock, debt and preferreds
|
2/27/2012 | CV | Market Commentary: Dendreon drops on outlook; Cheniere gains on Blackstone investment; DealerTrack to price
|
2/24/2012 | CV | Market Commentary: Interpublic slips in active trade on call; Salesforce.com active, lower; Savient weakens
|
12/30/2011 | CV | Outlook 2012: MF Global's two convertibles deals: A 'black eye' for the market
|
12/30/2011 | CV | Outlook 2012: Convertibles primary market set for weakness without higher rates, stronger economy
|
12/14/2011 | CV | Market Commentary: Lower-quality names succumb to selling; Savient drops; Cheniere up on secondary offering
|
11/14/2011 | CV | Market Commentary: Central European Distribution, Savient extend losses; Newer Human Genome premium rises
|
11/14/2011 | DD | Market Commentary: ATP Oil slips again; ResCap up ahead of coupon; Central European down in converts market
|
5/6/2011 | CV | Market Commentary: Lam Research issues expand on hedged basis on debuts; energy names expand on lower oil
|
2/7/2011 | CV | Market Commentary: Beckman 'comes in' on hedge; Chesapeake up on planned asset sale talk; MF Global on tap
|
2/4/2011 | CV | Savient greenshoe exercised, lifts 4.75% convertibles to $230 million
|
2/2/2011 | CV | Market Commentary: EMC, Amgen paper steady to higher; Savient extends gains; D.R. Horton, Lennar in trade
|
2/1/2011 | CV | New Issue: Savient prices upsized $200 million seven-year convertibles to yield 4.75%, up 25%
|
2/1/2011 | CV | Market Commentary: Upsized Savient jumps on debut; Avatar prices 7.5% convertibles; ADM gains after earnings
|
1/31/2011 | CV | Market Commentary: Massey Energy up on merger; Alpha Natural off; Savient upsizes; Avatar, Hovnanian on tap
|
1/31/2011 | CV | Savient Pharmaceuticals plans upsized $175 million seven-year convertibles at 4.5%-5%, up 20%-25%
|
7/24/2009 | SS | Market Commentary: Bristol-Meyers predicted to continue deal pace; proxy firm sides with Foundation Coal buyout
|
4/3/2009 | PP | New Issue: Savient plans $31 million offering of units
|
4/3/2009 | PP | Market Commentary: Greystar cancels C$50 million deal; Formation plans C$6.25 million unit sale; Savient to sell units
|
10/16/2007 | SP | New Issue: Eksportfinans prices $708,000 of 35.5% reverse convertibles linked to Savient via Natixis
|
10/15/2007 | SP | New Issue: Lehman sells $500,000 of 51.35% reverse exchangeables linked to Savient
|
10/15/2007 | SP | Market Commentary: Barclays plans more iPath offerings; Lehman hits 51.35% coupon
|
9/28/2007 | SP | Eksportfinans to price 35.5% reverse convertibles linked to Savient Pharmaceuticals via Natixis
|
9/24/2007 | CVHY | Savient Pharmaceuticals files $200 million shelf
|
10/30/2006 | BT | Savient's third-quarter sales boosted by Oxandrin
|
9/26/2006 | BT | Savient files patent infringement lawsuit against Barr
|
9/12/2006 | BT | Savient to repurchase 10 million shares in oversubscribed tender
|
8/14/2006 | BT | Savient to repurchase up to 10 million shares
|
8/4/2006 | BT | Savient sells Rosemont subsidiary for $176 million
|
7/6/2006 | BT | Market Commentary: Par shares plunge, convertible up with restatement; Savient up on new CFO; Gene Logic moves up
|
6/22/2006 | BT | Savient says additional phase 2 results promising for Puricase as gout treatment
|
6/14/2006 | BT | Savient begins patient dosing in phase 3 studies of Puricase for gout
|
5/3/2006 | BT | FDA approves Savient's replicate Puricase phase 3 trials for treatment of gout
|
4/24/2006 | BT | Cytogen, Savient finalize distribution agreement for Soltamox
|
4/24/2006 | BT | Market Commentary: DOV, Discovery Labs off huge after close; 3 deals emerge; GW up big; Ariad off on Amgen suit
|
4/19/2006 | BT | Savient Pharmaceuticals presents four abstracts on Puricase at rheumatology conference
|
3/21/2006 | BT | Savient, FDA agree on phase 3 protocol for Puricase in treatment of gout
|
2/17/2006 | BT | Savient to explore strategic alternatives for its Rosemont subsidiary
|
2/8/2006 | BT | Cytogen, Savient sign letter of intent to market Soltamox for breast cancer
|
1/31/2006 | BT | Savient regains compliance with Nasdaq listing requirements
|
1/26/2006 | BT | Savient meets filing deadline for required Nasdaq reports
|
1/23/2006 | BT | Savient Pharmaceuticals receives Nasdaq listing extension
|
1/13/2006 | BT | Savient requests second extension from Nasdaq to refile reports, prevent delisting
|
1/3/2006 | BT | Savient receives two-week extension from Nasdaq to refile reports, prevent delisting
|
12/22/2005 | BT | Savient asks Nasdaq to extend deadline for financial reports; terminates development of Prosaptide
|
12/13/2005 | BT | Savient agrees to sell testosterone product Delatestryl to Indevus for $5 million, share of sales
|
12/2/2005 | BT | Savient, Barr settle patent litigation; Barr gets rights to birth control pill Mircette for $13.75 million
|
11/18/2005 | BT | Nasdaq cites Savient for not filing timely quarterly report for period ended Sept. 30
|
11/14/2005 | BT | Savient's Puricase found to substantially reduce plasma urate levels in patients with gout
|
10/31/2005 | BT | Savient Pharmaceuticals receives FDA approval for oral tamoxifen
|
10/28/2005 | BT | Savient Pharmaceuticals receives filing extension from Nasdaq
|
8/19/2005 | BT | Savient gets Nasdaq delisting notice for late 10-Q
|